Ranolazine SR in Patients With Chronic Angina Who Remain Symptomatic Despite Maximal Treatment With Amlodipine
Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
The study will be a multi-national, double-blind, randomized, placebo-controlled, parallel
group study to evaluate the effectiveness of ranolazine (1000 mg twice daily) in
approximately 500 patients with chronic angina who remain symptomatic despite daily treatment
with the maximum labeled dose of amlodipine (10 mg daily), a calcium channel blocker approved
for the treatment of chronic angina. Eligible patients will be randomized to receive
ranolazine 1000 mg or placebo twice daily, in addition to a daily dose of 10 mg of
amlodipine. Participation in the study will last approximately 3 months.